T-box transcription factor TGenealiases: SAVA · T · TFT
Q-omics provides the consensus-scored TBXT profile across patient tissues and cancer cell-line models. TBXT expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, TBXT is differentially expressed in 5, with the highest sampling consensus in BRCA. Additionally, TBXT RNA expression shows 8,577 significant gene co-expression associations, with the highest sampling consensus in LIHC. Together, these results highlight LUSC, BRCA, and LIHC as cancer lineages where TBXT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TBXT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TBXT survival associations across molecular data types. TBXT RNA expression shows survival associations in the most cancer types (20), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TBXT RNA expression–survival associations across cancer types. High TBXT expression shows unfavorable associations in LUSC, LIHC, STAD, DLBC, KIRC and ACC. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for TBXT RNA expression.
This table summarizes TBXT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for TBXT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TBXT shows lower tumor expression in BRCA and READ and higher tumor expression in HNSC, LUAD and LUSC. The BRCA box plot shows higher TBXT RNA expression in normal versus tumor tissue (log2 FC = −0.084, t-test p < 0.001).
This table shows molecular features associated with TBXT in patient tissues and cancer cell lines. In patient samples, TBXT shows the broadest associations at the RNA and protein expression levels, with LIHC recurring as the lineage with the largest associated feature set. In cancer cell lines, TBXT RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LIVER and LARGE_INTESTINE.
